[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Coya Therapeutics Inc (COYA)

Coya Therapeutics Inc (COYA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 97,816
  • Shares Outstanding, K 23,457
  • Annual Sales, $ 7,950 K
  • Annual Income, $ -21,230 K
  • EBIT $ -23 M
  • EBITDA $ -23 M
  • 60-Month Beta 0.55
  • Price/Sales 12.49
  • Price/Cash Flow N/A
  • Price/Book 2.06

Options Overview Details

View History
  • Implied Volatility 492.33% (-23.64%)
  • Historical Volatility 66.47%
  • IV Percentile 79%
  • IV Rank 32.60%
  • IV High 1,324.92% on 02/10/26
  • IV Low 89.67% on 10/22/25
  • Expected Move (DTE 12) 0.51 (12.23%)
  • Put/Call Vol Ratio 999.99
  • Today's Volume 10
  • Volume Avg (30-Day) 21
  • Put/Call OI Ratio 0.05
  • Today's Open Interest 1,471
  • Open Int (30-Day) 1,483
  • Expected Range 3.66 to 4.68

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $-0.39
  • Number of Estimates 1
  • High Estimate $-0.39
  • Low Estimate $-0.39
  • Prior Year $-0.44
  • Growth Rate Est. (year over year) +11.36%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.90 +6.92%
on 04/07/26
5.08 -17.91%
on 04/20/26
+0.09 (+2.21%)
since 04/01/26
3-Month
3.71 +12.40%
on 03/30/26
5.32 -21.62%
on 02/10/26
-0.48 (-10.32%)
since 01/30/26
52-Week
3.71 +12.40%
on 03/30/26
7.75 -46.19%
on 10/14/25
-2.11 (-33.60%)
since 05/01/25

Most Recent Stories

More News
Coya Therapeutics Announces Publication Demonstrating Correlation Between Longitudinal Biomarker Data and Clinical Outcomes Supporting the Mechanistic Rationale for COYA 302 in Patients with ALS

The study evaluated serum biomarkers of lipid peroxidation, systemic inflammation, and axonal integrity in 100 randomly selected patients with ALS and included 100 healthy controls to allow for a meaningful...

COYA : 4.17 (-1.42%)
Coya Therapeutics Announces Planned Board Transition and Appointment of Mark H. Pavao as Independent Director

Howard Berman, Ph.D., the Company’s Founder and current Executive Chairman and Director, has stepped down from his roles, following the CEO transition process initiated in November 2024. ...

COYA : 4.17 (-1.42%)
Coya Therapeutics Announces Publication Demonstrating Regulatory T-Cell Dysfunction and Systemic Inflammation in Frontotemporal Dementia, Supporting Mechanistic Rationale for COYA 302 Immune-Restoring Therapy

Study results demonstrate significant reduction in regulatory T cell (Treg) function and significant increase in circulating pro-inflammatory cytokines and chemokines in patients with FTD ...

COYA : 4.17 (-1.42%)
Coya Therapeutics Provides a Corporate Update and Reports Fiscal 2025 Financial Results

Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance T-cell (Treg) function in patients with...

COYA : 4.17 (-1.42%)
Coya Therapeutics to Host Webinar with Leading Medical Experts on Amyotrophic Lateral Sclerosis (ALS) Drug Development, Patient Landscape, and Ongoing Clinical Trial

─ Virtual Webinar on Tuesday, Feb. 17 at 3 p.m. ET / 12 p.m. PT ─ Will feature discussion and insights from Fred Grossman, D.O., FAPA; Stanley Appel, M.D.;...

COYA : 4.17 (-1.42%)
Coya Therapeutics Announces $11.1 Million Private Placement

- Dr. Reddy’s Laboratories, Inc., a subsidiary of Coya’s current strategic collaborator, makes a $10 million investment - Greenlight Capital, Coya’s...

COYA : 4.17 (-1.42%)
Coya Therapeutics CEO Dr. Arun Swaminathan Issues Letter to Stockholders

Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance Treg function, releases the following letter...

COYA : 4.17 (-1.42%)
Coya Therapeutics Announces Results of Investigator-Initiated Study of LD IL-2 and CTLA4-Ig Demonstrating Treg Enhancement and Cognitive Stability in Frontotemporal Dementia Patients

Robust target engagement was observed, with statistically significant increases in regulatory T-cell (Treg) suppressive function and Treg numbers beginning as early as two weeks post-dosing and sustained...

COYA : 4.17 (-1.42%)
Coya Therapeutics Receives Clinical Trial Application (CTA) Acceptance from Health Canada to Proceed with the COYA 302 ALSTARS Trial for the Treatment of Amyotrophic Lateral Sclerosis (ALS)

The CTA No Objection Letter from Health Canada allows for initiation of patient enrollment in the ALSTARS Trial at Canadian ALS centers. The ALSTARS Trial is a phase 2, placebo-controlled study...

COYA : 4.17 (-1.42%)
Coya Therapeutics Announces Patients Have Been Dosed in the ALSTARS Trial of COYA 302 for the Treatment of ALS

The ALSTARS Trial is a Phase 2, multi-center, randomized, double-blind, placebo-controlled study to assess the safety and efficacy of COYA 302 in patients with amyotrophic lateral sclerosis (ALS) being...

COYA : 4.17 (-1.42%)

Business Summary

Coya Therapeutics Inc. is a clinical-stage biotechnology company. It involved in developing proprietary treatments focused on the biology and potential therapeutic advantages of regulatory T cells to target systemic inflammation and neuroinflammation. The company's therapeutic platforms include Treg-enhancing...

See More

Key Turning Points

3rd Resistance Point 4.45
2nd Resistance Point 4.38
1st Resistance Point 4.28
Last Price 4.17
1st Support Level 4.11
2nd Support Level 4.04
3rd Support Level 3.94

See More

52-Week High 7.75
Fibonacci 61.8% 6.21
Fibonacci 50% 5.73
Fibonacci 38.2% 5.25
Last Price 4.17
52-Week Low 3.71

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.